Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with Taxol in xenogeneic compartmental models of human ovarian carcinoma

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 573-581

  Auzenne, Edmond ^a   Donato, Nicholas J ^a   Li, Chun ^a   Leroux, Elena ^a   Price, Roger E ^a   Farquhar, David ^a   Klostergaard, Jim ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID PACLITAXEL COPOLYMER; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MORBIDITY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PACLITAXEL; POLYGLUTAMIC ACID; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036187909     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Cancer statistics, 1995
2. Epithelial ovarian cancer
3. Intraperitoneal cisplatin plus intravenous cyclophosphamide vs. intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian carcinoma
4. New platinum antitumor complexes
5. Platinum resistance: Laboratory findings and clinical implications
6. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia
7. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro
8. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II)
9. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells
10. Enhanced replicative bypass of platinum DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines
11. Plasma platinum levels: Relationship to cisplatin dose and nephrotoxicity
12. Cisplatin neurotoxicity
13. Neurotoxic side-effects of cisplatin
14. A peculiar toxicity manifested by platinum (II) amines in rats: Gastric distension after intraperitoneal administration
15. Paclitaxel (Taxol)
16. Taxol induced polymerization of purified tubulin. Mechanism of action
17. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins
18. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol
19. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations
20. Mechanisms of Taxol-induced cell death are concentration dependent
21. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization
22. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol)
23. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to Taxol and doxorubicin
24. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity
25. Recombinant humanized anti-HER2 antibody (Herecptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
26. Overexpression of c-erbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1 independent mechanisms
27. Chemosensitization of HER2/neu-overexpressing human breast cancer cells to paclitaxel Taxol) by adenovirus type 5 E1A
28. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol
29. On pushing the outer edge of the outer edge of paclitaxel's dosing envelope
30. Multi-center, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
31. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer: Results from CALGB 9342
32. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol®) in human tumor cell lines
33. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
34. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells
35. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: Possible explanation for failure of combination therapy
36. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer
37. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
38. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate
39. Passive tumor targeting of soluble macromolecules and drug conjugates
40. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
41. Solubility and stability of paclitaxel: Effects of buffers and cyclodextrins
42. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel
43. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel
44. Complete regression of well-established tumors using a novel water-soluble poly (L-glutamic acid)-paclitaxel conjugate
45. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors
46. Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy
47. Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors
48. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice
49. Emergence of CDDP-resistant cells from OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement
50. Human tumor xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole-body irradiation
51. Comparative properties of five human ovarian adenocarcinoma cell lines
52. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates
53. Pharmacokinetic determinants of activity and toxicity of antitumor agents
54. Anticancer agents coupled to [N-(2-hydroxypropyl)methacrylamide] copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro
55. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS
56. Tumoritropic and lymphotropic principles of macromolecular drugs
57. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues
58. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids
59. Inhibition of aminoglycoside-induced nephrotoxicity in rats by polyanionic peptides
60. Comparative assessment of poly-L-aspartic and poly-L-glutamic acids as protectants against gentamicin-induced renal lysosomal phospholipids, phospholipiduria and cell proliferation in rats
61. Carboxylic ester hydrolases
62. Lysosomal degradability of poly(alph-amino acids)
63. Optimization of macromolecular prodrugs of antitumor antibiotic adriamycin
64. Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice
65. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study